Treated according to the Nordic NOPHO ALL-2000 protocol, dic(9;20)positive pediatric ALL is associated with a significantly higher risk of relapse compared with other standard risk aberrations, such as t(12;21)(p13;q22) and high hyperdiploidy, suggesting that dic(9;20) should be considered a nonstandard risk abnormality. The dic(9;20) translocation is present in up to 5% of childhood BCP ALL; however, it easily escapes detection by traditional cytogenetic approaches because of the subtle nature of the aberration. 1 We have previously described a three-step approach to detect dic(9;20) using interphase fluorescence in situ hybridization (FISH), utilizing the unbalanced nature of the rearrangement, to identify, in a sequential order, the 9p21 deletions, 20p/20q imbalances and co-localization of centromeres 9 and 20 associated with dic(9;20).
and Nordgren, unpublished data), but it is not clear whether such cases are biologically and/or clinically distinct from dic(9;20)-positive ALLs. Furthermore, at present, only a few laboratories perform array analyses in routine diagnostics of ALLs. In addition, unlike genomic arrays, FISH can reliably be used to visualize dic(9;20) on metaphases and to detect samples with low-level mosaicism at diagnosis or during follow-up. For these reasons, we consider FISH to be the current method of choice for reliable detection of dic(9;20) in a routine clinical setting.
To develop a FISH probe that would detect all dic(9;20)-positive BCP ALL, we mined breakpoint data from all previously reported cases ( Figure 1) . 9 On the basis of these breakpoints, we designed a set of probes that collectively detect: (i) the unbalanced loss of 20q material, regardless of whether one or two normal chromosome 20 homologs are present, and (ii) the co-localization of centromeres 9 and 20. Specifically, the probe on 20q is located just distal of the most telomeric breakpoints reported in dic(9;20) (Figure 1) , resulting, if positive, in loss of one signal from 20q while still being close enough to ensure the probe's specificity. For the co-localization signal of centromeres 9 and 20, several versions, with minor variations in genomic position and probe size, were tested on individual positive and negative controls before deciding on a final design, shown consistently to produce strong and homogeneous signals. The centromere 20 (SE20) probe was ruled Letters to the Editor out due to great interindividual variations in signal intensity. BACs covering the specified area on 20q11 were sent to Kreatech Diagnostics (Amsterdam, the Netherlands) where they were labeled with green and mixed with a centromere-specific probe for chromosome 9 (SE9) labeled with blue and a 20p11 probe labeled with red ( Figure 1 ). All bone marrow slides were prepared according to the manufacturer's instructions (Kreatech Diagnostics) and analyzed using a Zeiss Axioskop 2 (Carl Zeiss, Gö ttingen, Germany) and Smart Capture 3 software (Digital Scientific Ltd, Cambridge, UK).
To validate the probe kit, we initially tested it on interphase nuclei and metaphase chromosomes from diagnostic bone marrow samples of previously identified dic(9;20)-positive cases-four with monosomy 20 and one with two normal chromosome 20 homologs (Figure 2 ). In addition, more than 50 negative controls were screened (both normal blood and dic(9;20)-negative ALL cases; Figure 2 ), for which additional cytogenetic information was available through traditional G-banding, targeted FISH and, in all but seven cases, either spectral karyotyping or array-based analyses. No false-positive cases were detected among the controls using a 3% positive threshold ( þ 3 s.d. from the mean), counting at least 200 nuclei where possible. Since having implemented this probe kit in our routine diagnostic workup of childhood ALL, we have detected two additional cases of dic(9;20)-positive BCP ALL: a 5-year-old female with 93% dic(9;20)-positive cells detectable at diagnosis and a 21-year-old male, in which dic(9;20) was present as a minor clone (o10%) in interphase nuclei and metaphase spreads (9 of 81 scored metaphases) at diagnosis and was not picked up by either karyotyping or array analysis.
In summary, we have developed a three-color FISH probe kit for the detection of dic(9;20) in BCP ALL. The design was based on available breakpoint data from reported dic(9;20)-positive ALL and the probe kit performed well when evaluated and later implemented in a clinical setting, as well as in research.
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